Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates

Peter B. Jahrling; Joan B. Geisbert; James R. Swearengen; Thomas Larsen; Thomas W. Geisbert

doi:10.1086/520587

Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates

Peter B. Jahrling, Joan B. Geisbert, James R. Swearengen, Thomas Larsen, Thomas W. Geisbert

Research output: Contribution to journal › Article › peer-review

113 Scopus citations

Abstract

The survival of 7 of 8 patients with Ebola virus (EBOV) infection after transfusions of convalescent-phase blood during a 1995 outbreak of EBOV infection is frequently cited as evidence that passive immunotherapy is a viable treatment option. To test whether whole-blood transfusions were more efficacious than passively administered immunoglobulins or monoclonal antibodies, we transfused convalescent-phase blood from EBOV-immune monkeys into naive animals shortly after challenge with EBOV. Although passively acquired antibody titers comparable to those associated with effective vaccination were obtained, all monkeys that had received transfusions succumbed to infection concurrently with control monkeys. These data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infection.

Original language	English (US)
Pages (from-to)	S400-S403
Journal	Journal of Infectious Diseases
Volume	196
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1086/520587
State	Published - Nov 15 2007
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1086/520587

Cite this

@article{f01e4fc8abb047998a60a35ac102ea67,

title = "Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates",

abstract = "The survival of 7 of 8 patients with Ebola virus (EBOV) infection after transfusions of convalescent-phase blood during a 1995 outbreak of EBOV infection is frequently cited as evidence that passive immunotherapy is a viable treatment option. To test whether whole-blood transfusions were more efficacious than passively administered immunoglobulins or monoclonal antibodies, we transfused convalescent-phase blood from EBOV-immune monkeys into naive animals shortly after challenge with EBOV. Although passively acquired antibody titers comparable to those associated with effective vaccination were obtained, all monkeys that had received transfusions succumbed to infection concurrently with control monkeys. These data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infection.",

author = "Jahrling, {Peter B.} and Geisbert, {Joan B.} and Swearengen, {James R.} and Thomas Larsen and Geisbert, {Thomas W.}",

note = "Funding Information: Supplement sponsorship. This article was published as part of a supplement entitled “Filoviruses: Recent Advances and Future Challenges,” sponsored by the Public Health Agency of Canada, the National Institutes of Health, the Canadian Institutes of Health Research, Cangene, CUH2A, Smith Carter, Hemisphere Engineering, Crucell, and the International Centre for Infectious Diseases. Funding Information: Financial support: Defense Threat Reduction Agency and the Medical Chemical/ Biological Defense Research Program, US Army Medical Research and Material Command (project 02-4-4J-084). Supplement sponsorship is detailed in the Acknowledgments.",

year = "2007",

month = nov,

day = "15",

doi = "10.1086/520587",

language = "English (US)",

volume = "196",

pages = "S400--S403",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Ebola hemorrhagic fever

T2 - Evaluation of passive immunotherapy in nonhuman primates

AU - Jahrling, Peter B.

AU - Geisbert, Joan B.

AU - Swearengen, James R.

AU - Larsen, Thomas

AU - Geisbert, Thomas W.

N1 - Funding Information: Supplement sponsorship. This article was published as part of a supplement entitled “Filoviruses: Recent Advances and Future Challenges,” sponsored by the Public Health Agency of Canada, the National Institutes of Health, the Canadian Institutes of Health Research, Cangene, CUH2A, Smith Carter, Hemisphere Engineering, Crucell, and the International Centre for Infectious Diseases. Funding Information: Financial support: Defense Threat Reduction Agency and the Medical Chemical/ Biological Defense Research Program, US Army Medical Research and Material Command (project 02-4-4J-084). Supplement sponsorship is detailed in the Acknowledgments.

PY - 2007/11/15

Y1 - 2007/11/15

N2 - The survival of 7 of 8 patients with Ebola virus (EBOV) infection after transfusions of convalescent-phase blood during a 1995 outbreak of EBOV infection is frequently cited as evidence that passive immunotherapy is a viable treatment option. To test whether whole-blood transfusions were more efficacious than passively administered immunoglobulins or monoclonal antibodies, we transfused convalescent-phase blood from EBOV-immune monkeys into naive animals shortly after challenge with EBOV. Although passively acquired antibody titers comparable to those associated with effective vaccination were obtained, all monkeys that had received transfusions succumbed to infection concurrently with control monkeys. These data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infection.

AB - The survival of 7 of 8 patients with Ebola virus (EBOV) infection after transfusions of convalescent-phase blood during a 1995 outbreak of EBOV infection is frequently cited as evidence that passive immunotherapy is a viable treatment option. To test whether whole-blood transfusions were more efficacious than passively administered immunoglobulins or monoclonal antibodies, we transfused convalescent-phase blood from EBOV-immune monkeys into naive animals shortly after challenge with EBOV. Although passively acquired antibody titers comparable to those associated with effective vaccination were obtained, all monkeys that had received transfusions succumbed to infection concurrently with control monkeys. These data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infection.

UR - http://www.scopus.com/inward/record.url?scp=38449092660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449092660&partnerID=8YFLogxK

U2 - 10.1086/520587

DO - 10.1086/520587

M3 - Article

C2 - 17940976

AN - SCOPUS:38449092660

SN - 0022-1899

VL - 196

SP - S400-S403

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - SUPPL. 2

ER -

Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this